vs
ANI PHARMACEUTICALS INC（ANIP）とKADANT INC（KAI）の財務データ比較。上の社名をクリックして会社を切り替えられます
KADANT INCの直近四半期売上が大きい（$271.6M vs $247.1M、ANI PHARMACEUTICALS INCの約1.1倍）。ANI PHARMACEUTICALS INCの純利益率が高く（11.1% vs 10.2%、差は0.9%）。ANI PHARMACEUTICALS INCの前年同期比売上増加率が高い（29.6% vs -0.0%）。KADANT INCの直近四半期フリーキャッシュフローが多い（$44.1M vs $29.1M）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs 6.7%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
Kadant Inc.は1991年に設立され、当初はThermo Electronの子会社として一部が私有、一部が公開取引されていたが、2001年に完全分離し現在の社名に変更した。製紙、古紙リサイクル、木材加工、荷役などの産業向けにサービスを提供し、アジア、ヨーロッパ、北米、南米に事業を展開する多国籍企業である。
ANIP vs KAI — 直接比較
損益計算書 — Q4 FY2025 vs Q3 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $271.6M |
| 純利益 | $27.5M | $27.7M |
| 粗利率 | — | 45.2% |
| 営業利益率 | 14.1% | 15.7% |
| 純利益率 | 11.1% | 10.2% |
| 売上前年比 | 29.6% | -0.0% |
| 純利益前年比 | 367.5% | -12.2% |
| EPS（希薄化後） | $1.14 | $2.35 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $247.1M | — | ||
| Q3 25 | $227.8M | $271.6M | ||
| Q2 25 | $211.4M | $255.3M | ||
| Q1 25 | $197.1M | $239.2M | ||
| Q4 24 | $190.6M | $258.0M | ||
| Q3 24 | $148.3M | $271.6M | ||
| Q2 24 | $138.0M | $274.8M | ||
| Q1 24 | $137.4M | $249.0M |
| Q4 25 | $27.5M | — | ||
| Q3 25 | $26.6M | $27.7M | ||
| Q2 25 | $8.5M | $26.2M | ||
| Q1 25 | $15.7M | $24.1M | ||
| Q4 24 | $-10.3M | $24.0M | ||
| Q3 24 | $-24.2M | $31.6M | ||
| Q2 24 | $-2.3M | $31.3M | ||
| Q1 24 | $18.2M | $24.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | 45.2% | ||
| Q2 25 | — | 45.9% | ||
| Q1 25 | — | 46.1% | ||
| Q4 24 | — | 43.4% | ||
| Q3 24 | — | 44.7% | ||
| Q2 24 | — | 44.4% | ||
| Q1 24 | — | 44.6% |
| Q4 25 | 14.1% | — | ||
| Q3 25 | 15.9% | 15.7% | ||
| Q2 25 | 6.6% | 15.4% | ||
| Q1 25 | 13.3% | 14.9% | ||
| Q4 24 | -2.3% | 14.3% | ||
| Q3 24 | -13.8% | 18.0% | ||
| Q2 24 | 3.7% | 17.6% | ||
| Q1 24 | 14.8% | 14.8% |
| Q4 25 | 11.1% | — | ||
| Q3 25 | 11.7% | 10.2% | ||
| Q2 25 | 4.0% | 10.2% | ||
| Q1 25 | 8.0% | 10.1% | ||
| Q4 24 | -5.4% | 9.3% | ||
| Q3 24 | -16.3% | 11.6% | ||
| Q2 24 | -1.7% | 11.4% | ||
| Q1 24 | 13.2% | 9.9% |
| Q4 25 | $1.14 | — | ||
| Q3 25 | $1.13 | $2.35 | ||
| Q2 25 | $0.36 | $2.22 | ||
| Q1 25 | $0.69 | $2.04 | ||
| Q4 24 | $-0.45 | $2.04 | ||
| Q3 24 | $-1.27 | $2.68 | ||
| Q2 24 | $-0.14 | $2.66 | ||
| Q1 24 | $0.82 | $2.10 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | $124.5M |
| 総負債低いほど良い | — | $254.6M |
| 株主資本純資産 | $540.7M | $949.8M |
| 総資産 | $1.4B | $1.5B |
| 負債/資本比率低いほどレバレッジが低い | — | 0.27× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $285.6M | — | ||
| Q3 25 | $262.6M | $124.5M | ||
| Q2 25 | $217.8M | $95.3M | ||
| Q1 25 | $149.8M | $91.7M | ||
| Q4 24 | $144.9M | $94.7M | ||
| Q3 24 | $145.0M | $88.4M | ||
| Q2 24 | $240.1M | $73.8M | ||
| Q1 24 | $228.6M | $81.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | $254.6M | ||
| Q2 25 | — | $245.7M | ||
| Q1 25 | — | $273.5M | ||
| Q4 24 | — | $285.2M | ||
| Q3 24 | — | $323.2M | ||
| Q2 24 | — | $342.0M | ||
| Q1 24 | — | $306.8M |
| Q4 25 | $540.7M | — | ||
| Q3 25 | $505.8M | $949.8M | ||
| Q2 25 | $436.8M | $926.0M | ||
| Q1 25 | $418.6M | $876.0M | ||
| Q4 24 | $403.7M | $847.1M | ||
| Q3 24 | $405.9M | $851.7M | ||
| Q2 24 | $455.8M | $807.7M | ||
| Q1 24 | $452.0M | $782.7M |
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.4B | $1.5B | ||
| Q2 25 | $1.3B | $1.5B | ||
| Q1 25 | $1.3B | $1.4B | ||
| Q4 24 | $1.3B | $1.4B | ||
| Q3 24 | $1.3B | $1.5B | ||
| Q2 24 | $920.8M | $1.5B | ||
| Q1 24 | $914.5M | $1.4B |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.27× | ||
| Q1 25 | — | 0.31× | ||
| Q4 24 | — | 0.34× | ||
| Q3 24 | — | 0.38× | ||
| Q2 24 | — | 0.42× | ||
| Q1 24 | — | 0.39× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $47.3M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | $44.1M |
| FCFマージンFCF / 売上 | 11.8% | 16.2% |
| 設備投資強度設備投資 / 売上 | 0.5% | 1.2% |
| キャッシュ転換率営業CF / 純利益 | 1.10× | 1.70× |
| 直近12ヶ月FCF直近4四半期 | $171.4M | $145.9M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $30.4M | — | ||
| Q3 25 | $44.1M | $47.3M | ||
| Q2 25 | $75.8M | $40.5M | ||
| Q1 25 | $35.0M | $22.8M | ||
| Q4 24 | $15.9M | $51.9M | ||
| Q3 24 | $12.5M | $52.5M | ||
| Q2 24 | $17.4M | $28.1M | ||
| Q1 24 | $18.3M | $22.8M |
| Q4 25 | $29.1M | — | ||
| Q3 25 | $38.0M | $44.1M | ||
| Q2 25 | $71.8M | $36.5M | ||
| Q1 25 | $32.5M | $19.0M | ||
| Q4 24 | $13.5M | $46.3M | ||
| Q3 24 | $7.7M | $48.3M | ||
| Q2 24 | $13.0M | $23.1M | ||
| Q1 24 | $13.7M | $16.6M |
| Q4 25 | 11.8% | — | ||
| Q3 25 | 16.7% | 16.2% | ||
| Q2 25 | 34.0% | 14.3% | ||
| Q1 25 | 16.5% | 7.9% | ||
| Q4 24 | 7.1% | 17.9% | ||
| Q3 24 | 5.2% | 17.8% | ||
| Q2 24 | 9.4% | 8.4% | ||
| Q1 24 | 10.0% | 6.7% |
| Q4 25 | 0.5% | — | ||
| Q3 25 | 2.7% | 1.2% | ||
| Q2 25 | 1.9% | 1.6% | ||
| Q1 25 | 1.3% | 1.6% | ||
| Q4 24 | 1.3% | 2.2% | ||
| Q3 24 | 3.2% | 1.5% | ||
| Q2 24 | 3.2% | 1.8% | ||
| Q1 24 | 3.3% | 2.5% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | 1.70× | ||
| Q2 25 | 8.87× | 1.55× | ||
| Q1 25 | 2.23× | 0.95× | ||
| Q4 24 | — | 2.16× | ||
| Q3 24 | — | 1.66× | ||
| Q2 24 | — | 0.90× | ||
| Q1 24 | 1.00× | 0.92× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
KAI
| Flow Control | $94.8M | 35% |
| Capital | $83.2M | 31% |
| Material Handling Systems | $70.3M | 26% |
| Transferred Over Time | $17.1M | 6% |
| Other | $6.1M | 2% |
